MRPL32 and central nervous system cancer: Prior studies demonstrated that suppressing MRPL32 could reduce oxygen-glucose deprivation/reperfusion damage (Guan et al., 2020) and that REXO2 was associated with a poorer prognosis in glioma (Wang et al., 2021).